Daisynone tablets 500 grams - 20 tablets

50.60

Out of Stock

Product description

Etamsilat solution for injection 500 mg / 5 ml * What is Etamsilat and what are its indications for use Etamsilat belongs to a group of medicines called hemostatic agents. Fibrin inhibitors, amino acids. Etamsilat is used in adults and children over one year old for prevention and treatment of bleeding due to a process that prevents blood clotting called fibrinolysis. Specific uses include: • Heavy periods in women. • Gastrointestinal bleeding; • Hemorrhagic urinary tract disorders after surgery on the prostate gland or urinary tract. • After surgery on your ear or nose or throat; • After surgery on the heart or abdomen or gynecology. • Bleeding after treatment with another drug to dissolve blood clots. What you need to know before using Etamsilat Do not use Etamsilat Tell your doctor if any of the following apply to you before starting this medication inform your doctor if: • You have a severe allergy to Etamsilat or any other ingredients of this medicine • You have had or previously had a disease that causes blood clotting. • You have a condition called "disseminated intravascular coagulation" where blood throughout the body begins to clot. • You have kidney problems. • You have a history of seizures (convulsions). Precautions and warnings You should inform your doctor of the following: • If you have blood in your urine, which may indicate a clot in the upper urinary tract. • If you are at risk of blood clots. • If you suffer from excessive clotting or bleeding throughout your body (disseminated intravascular coagulation). Your doctor may perform a blood test to determine if the process that prevents blood clotting (called fibrinolysis) has been activated; • If you have seizures (convulsions). Your doctor will use the lowest possible dose to avoid further seizures after treatment; • If you are on long-term treatment with Etamsilat, pay attention to any potential color vision disturbances. If necessary, your doctor may stop the treatment. Regular eye tests are recommended for long-term use of Etamsilat. If changes are observed in your eyes, your doctor may refer you to an ophthalmologist to decide whether to continue treatment. Other medicines and Etamsilat inform your doctor about the medicines you are taking, especially tell your doctor if you are taking: • Other medicines that help blood clotting, called antifibrinolytic drugs. • Medicines that prevent blood clotting, called anticoagulants. • Oral contraceptives. How to use Etamsilat Your doctor will decide the correct dose for you and the duration of use. Use in adults • Local fibrinolysis treatment: The usual dose is 500-1000 mg three times a day. • General fibrinolysis treatment: The usual dose is 1000 mg every 6 to 8 hours or up to 15 mg per kg of body weight. Use in children • The doctor will decide the appropriate dose for your child and the duration of use. • If Etamsilat is given to a child over one year old, the dose will depend on the child's body weight. Use in the elderly It is not necessary to reduce the dose unless you have kidney problems. Use in patients with kidney problems If you have kidney problems, the dose may be reduced. Your doctor will decide the dose to be given based on blood tests. Use in patients with liver problems There is no need to reduce the dose. Possible side effects Stop using the product and seek medical care immediately if • Swelling of the face, lips, tongue, or throat which may cause difficulty breathing or swallowing • Signs of blood clotting How to store Etamsilat • Keep all medicines out of reach and sight of children. • Do not store above 25°C. Keep in the original packaging. Do not freeze or refrigerate. • Do not use this medicine after the expiration date printed on the strip. • Do not dispose of medicines in the drain or trash. Ask your pharmacist what to do with any medicines you no longer want. This helps protect the environment. * The dosage form and method of administration of Etamsilat should be prescribed according to the therapeutic indication and the severity of the disease for each patient individually.

Questions you might have

‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌
‌
‌‌
‌